Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Albumin Excipient Market Set To Climb From $5.46 Billion In 2026 To $7.15 Billion By 2030
The albumin excipient market has experienced significant expansion over the past few years. Projections indicate it will expand from $5.15 billion in 2025 to $5.47 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by factors such as the increasing demand for biologics, enhanced research into protein-based excipients, an uptick in pharmaceutical manufacturing, the embrace of recombinant albumin, and advancements in stabilized formulations.
The albumin excipient market is projected to experience substantial expansion over the coming years, reaching $7.15 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This anticipated growth throughout the forecast period stems from factors such as the expanding biopharmaceutical sector, advancements in protein excipient technology, the increasing incidence of chronic diseases, an uptick in contract manufacturing, and a rise in regulatory approvals for new drug formulations. Key trends anticipated during this period encompass innovations in protein stabilization, progress in excipient formulation, improved drug delivery systems, adherence to regulatory compliance and GMP standards, and optimization of supply chains.
Get A Free Sample Report With In-Depth Market Insights:
Albumin Excipient Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of chronic illnesses is projected to drive the expansion of the albumin excipient market. These diseases are characterized by their duration of three months or more, often worsening over time. Albumin, which is the most abundant circulating protein in plasma, functions as a blood volumizer. Furthermore, it acts as a versatile protein carrier, essential for drug targeting and for improving the pharmacokinetic profile of peptide or protein-based medications utilized in the treatment of various conditions, including cancer and diabetes. For instance, in February 2024, the World Health Organization, a Switzerland-based agency of the United Nations, projected that over 35 million new cancer cases will emerge by 2050, indicating a 77% increase from the estimated 20 million cases in 2022. Thus, the escalating prevalence of chronic diseases is a key driver for the growth of the albumin excipient market.
Albumin Excipient Market Breakdown By Product Type And Application
The albumin excipient market covered in this report is segmented –
1) By Product: Human Serum Albumin, Recombinant Albumin
2) By End-Users: Pharmaceutical And Biotechnology Industry, Research Institutes, Other End Users
3) By Application Type: Injectable Formulations, Vaccine Formulations, Cell Culture Or Bioprocessing, Diagnostic Formulations
Subsegments:
1) By Human Serum Albumin: 5% Human Serum Albumin, 20% Human Serum Albumin
2) By Recombinant Albumin: Recombinant Human Serum Albumin, Recombinant Bovine Serum Albumin
Albumin Excipient Market Trends Redefining Industry Growth
Major companies operating in the albumin excipient market are adopting strategic partnership approaches to serve the essential biotechnology and pharmaceutical sectors. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company, partnered with Basic Pharma, a Netherlands-based pharmaceutical company, to advance recombinant protein production. Through this partnership, they aim to improve pharmaceutical recombinant protein production by streamlining the supply chain and reducing the time-to-market for new products.
Albumin Excipient Market Company Landscape And Competitive Strategy
Major companies operating in the albumin excipient market are Albumin Therapeutics LLC, Biotest AG, CSL Behring, Grifols S.A., InVitria Inc., Octapharma AG, Kedrion Biopharma, LFB USA Inc., Baxter International Inc., Merck KGaA, Albumedix A/S, Bio Products Laboratory Ltd., Ventria Bioscience Inc., Novartis AG, China Biologic Products Holdings Inc., ProMetic Life Sciences Inc., Sanquin, Takeda Pharmaceutical Company Limited, FUJIFILM Irvine Scientific Inc., Shire Plc, Biopharma, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd.
View The Full Albumin Excipient Market Report:
Albumin Excipient Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the Albumin Excipient market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global albumin excipient market report during the forecast period. The regions covered in the albumin excipient market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
